These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25977981)

  • 1. Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2.
    Ward RA; Colclough N; Challinor M; Debreczeni JE; Eckersley K; Fairley G; Feron L; Flemington V; Graham MA; Greenwood R; Hopcroft P; Howard TD; James M; Jones CD; Jones CR; Renshaw J; Roberts K; Snow L; Tonge M; Yeung K
    J Med Chem; 2015 Jun; 58(11):4790-801. PubMed ID: 25977981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors.
    Aronov AM; Baker C; Bemis GW; Cao J; Chen G; Ford PJ; Germann UA; Green J; Hale MR; Jacobs M; Janetka JW; Maltais F; Martinez-Botella G; Namchuk MN; Straub J; Tang Q; Xie X
    J Med Chem; 2007 Mar; 50(6):1280-7. PubMed ID: 17300186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point.
    Ward RA; Bethel P; Cook C; Davies E; Debreczeni JE; Fairley G; Feron L; Flemington V; Graham MA; Greenwood R; Griffin N; Hanson L; Hopcroft P; Howard TD; Hudson J; James M; Jones CD; Jones CR; Lamont S; Lewis R; Lindsay N; Roberts K; Simpson I; St-Gallay S; Swallow S; Tang J; Tonge M; Wang Z; Zhai B
    J Med Chem; 2017 Apr; 60(8):3438-3450. PubMed ID: 28376306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2.
    Ren L; Grina J; Moreno D; Blake JF; Gaudino JJ; Garrey R; Metcalf AT; Burkard M; Martinson M; Rasor K; Chen H; Dean B; Gould SE; Pacheco P; Shahidi-Latham S; Yin J; West K; Wang W; Moffat JG; Schwarz JB
    J Med Chem; 2015 Feb; 58(4):1976-91. PubMed ID: 25603482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides.
    Schirmer A; Kennedy J; Murli S; Reid R; Santi DV
    Proc Natl Acad Sci U S A; 2006 Mar; 103(11):4234-9. PubMed ID: 16537514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERK1/2 MAP kinases: structure, function, and regulation.
    Roskoski R
    Pharmacol Res; 2012 Aug; 66(2):105-43. PubMed ID: 22569528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-gel activity-based protein profiling of a clickable covalent ERK1/2 inhibitor.
    Lebraud H; Wright DJ; East CE; Holding FP; O'Reilly M; Heightman TD
    Mol Biosyst; 2016 Aug; 12(9):2867-74. PubMed ID: 27385078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Slow inhibition and conformation selective properties of extracellular signal-regulated kinase 1 and 2 inhibitors.
    Rudolph J; Xiao Y; Pardi A; Ahn NG
    Biochemistry; 2015 Jan; 54(1):22-31. PubMed ID: 25350931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2.
    Heightman TD; Berdini V; Braithwaite H; Buck IM; Cassidy M; Castro J; Courtin A; Day JEH; East C; Fazal L; Graham B; Griffiths-Jones CM; Lyons JF; Martins V; Muench S; Munck JM; Norton D; O'Reilly M; Palmer N; Pathuri P; Reader M; Rees DC; Rich SJ; Richardson C; Saini H; Thompson NT; Wallis NG; Walton H; Wilsher NE; Woolford AJ; Cooke M; Cousin D; Onions S; Shannon J; Watts J; Murray CW
    J Med Chem; 2018 Jun; 61(11):4978-4992. PubMed ID: 29775310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and structure activity relationship study of novel indazole amide inhibitors for extracellular signal-regulated kinase1/2 (ERK1/2).
    Li L; Liu F; Jin N; Tang S; Chen Z; Yang X; Ding J; Geng M; Jiang L; Huang M; Cao J
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2600-4. PubMed ID: 27106711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular modeling and crystal structure of ERK2-hypothemycin complexes.
    Rastelli G; Rosenfeld R; Reid R; Santi DV
    J Struct Biol; 2008 Oct; 164(1):18-23. PubMed ID: 18571434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ERK1/2 signaling pathway regulates 11beta-hydroxysteroid dehydrogenase type 2 expression in human trophoblast cells through a transcriptional mechanism.
    Guan H; Sun K; Yang K
    Biol Reprod; 2013 Oct; 89(4):92. PubMed ID: 23966319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure.
    Chen F; Hancock CN; Macias AT; Joh J; Still K; Zhong S; MacKerell AD; Shapiro P
    Bioorg Med Chem Lett; 2006 Dec; 16(24):6281-7. PubMed ID: 17000106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).
    Lovering F; Kirincich S; Wang W; Combs K; Resnick L; Sabalski JE; Butera J; Liu J; Parris K; Telliez JB
    Bioorg Med Chem; 2009 May; 17(9):3342-51. PubMed ID: 19364658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flagellin and lipopolysaccharide stimulate the MEK-ERK signaling pathway in chicken heterophils through differential activation of the small GTPases, Ras and Rap1.
    Kogut MH; Genovese KJ; He H
    Mol Immunol; 2007 Mar; 44(7):1729-36. PubMed ID: 17045653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.
    Aronov AM; Tang Q; Martinez-Botella G; Bemis GW; Cao J; Chen G; Ewing NP; Ford PJ; Germann UA; Green J; Hale MR; Jacobs M; Janetka JW; Maltais F; Markland W; Namchuk MN; Nanthakumar S; Poondru S; Straub J; ter Haar E; Xie X
    J Med Chem; 2009 Oct; 52(20):6362-8. PubMed ID: 19827834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
    Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
    Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex.
    Ohori M; Kinoshita T; Okubo M; Sato K; Yamazaki A; Arakawa H; Nishimura S; Inamura N; Nakajima H; Neya M; Miyake H; Fujii T
    Biochem Biophys Res Commun; 2005 Oct; 336(1):357-63. PubMed ID: 16139248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
    Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA
    J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.